• 2022 consolidated turnover of €5.3 million net of studies for ABIONYX
• Continuation of clinical development in renal diseases following the positive clinical results of the Phase 2a RACERS study in sepsis
• Cash of €4.0 million as of December 31, 2022
• Announcement of the biotech strategy in ophthalmology during the month of March 2023
Toulouse, FRANCE, Lakeland, UNITED STATES, February 28, 2023, 6:00 p.m. – ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies, provides an update today today on its activity and cash and cash equivalents as of December 31, 2022.